POZN ($10.86)…Vimovo is a featured product for Astra Zeneca in their 2009 Shareholder Meeting. POZN is not alone in wanting this product to be approved! A lot on the line here and POZN has a key partner in the U.S. and internationally. images.investorshub.advfn.com/images/uploads/2010/3/31/nbiokAZ_1.JPG images.investorshub.advfn.com/images/uploads/2010/3/31/glqklAZ_2.JPG images.investorshub.advfn.com/images/uploads/2010/3/31/vksisAZ_3.JPG images.investorshub.advfn.com/images/uploads/2010/3/31/weobiAZ_4.JPG images.investorshub.advfn.com/images/uploads/2010/3/31/i[cnkAZ_6.JPG